-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EOI3AIfu+rCTiTZtoyRsIsMpv2RTGlSz82Wq7rR9BSMnNAjOysKgACUll6Q+5Sod IYbHPyRJ36BZnFodl7q1wQ== 0000875320-09-000004.txt : 20090206 0000875320-09-000004.hdr.sgml : 20090206 20090206161530 ACCESSION NUMBER: 0000875320-09-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090205 FILED AS OF DATE: 20090206 DATE AS OF CHANGE: 20090206 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOGER KENNETH S CENTRAL INDEX KEY: 0001046336 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 09577452 BUSINESS ADDRESS: STREET 1: 10 ALVIN COURT STREET 2: C/O ECOSCIENCE CORP CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 9084328200 MAIL ADDRESS: STREET 1: C/O ECOSCIENCE CORP STREET 2: 10 ALVIN COURT CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2009-02-05 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001046336 BOGER KENNETH S C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP & General Counsel Common Stock 2009-02-05 4 A 0 10166 .01 A 107683 D Common Stock 3561 I 401(k) Common Stock 1000 I Shares held by minor child. Stock Option 33.55 2009-02-05 4 A 0 45750 0 A 2009-05-05 2019-02-04 Common Stock 45750 45750 D Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Kenneth S. Boger 2009-02-06 -----END PRIVACY-ENHANCED MESSAGE-----